云南白药与华润三九的财务分析与股票估值研究
| dc.contributor.advisor | 吴世农 | |
| dc.contributor.author | 王月燕 | |
| dc.date.accessioned | 2022-01-12T07:19:43Z | |
| dc.date.available | 2022-01-12T07:19:43Z | |
| dc.date.issued | 2018-11-01 | |
| dc.date.replied | 2018-05-13 | |
| dc.description.abstract | 中成药是中华民族传承了五千年的文化瑰宝，是我国人民医疗实践的结晶。本文选取云南白药和华润三九这两家在中成药行业中实力与排名均较前的上市公司作为研究对象，通过分析其2012-2016年间的财务及经营数据来对比研究两家公司的财务绩效、财务政策和发展战略；并结合运用自由现金流模型和市盈率模型，对两家公司的未来5年股价进行估值研究。希望通过这一研究主题，比较分析两家公司各自的经营和财务状况，对其未来发展前景提出有用建议，也希望通过估值分析为投资者的投资决策提供客观、科学的依据。 本文共分为六章，第一章阐述研究背景，提出研究的主要问题和意义，确定研究方法、研究思路与框架；并对后文将运用到的文献进行系统... | |
| dc.description.abstract | Chinese traditional medicine is a treasure of 5,000 years, and a crystallization of thousands of years of medical practice. This paper chooses Yunnan Baiyao and Huarun Sanjiu, two listed companies whose strength and rank are both in the proprietary Chinese traditional medicine industry, as the research objects. Through analysis of the financial performance of the two companies from 2012 to 2016, w... | |
| dc.description.note | 学位：工商管理硕士专业学位 | |
| dc.description.note | 院系专业：管理学院_工商管理硕士 | |
| dc.identifier.uri | https://dspace.xmu.edu.cn/handle/2288/194589 | |
| dc.language.iso | zh_CN | |
| dc.source.uri | https://etd.xmu.edu.cn/detail.asp?serial=9A7B7E96-8268-4A16-8BF2-58F3AAA8FC09 | |
| dc.subject | 中成药行业 | |
| dc.subject | 财务分析 | |
| dc.subject | 股票估值 | |
| dc.subject | Chinese traditional medicine industry | |
| dc.subject | financial analysis | |
| dc.subject | stock valuation | |
| dc.title | 云南白药与华润三九的财务分析与股票估值研究 | |
| dc.title.alternative | A Research on the Financial Performance and Stock Valuation of Yunnan Baiyao and Huarun Sanjiu | |
| dc.type | thesis |
Files
Original bundle
1 - 1 of 1